Financials

News Ideas Discussions Forecast Seasonals

6C1 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to CYTOMX THERAPEUTIC operating, investing, and financing activities

6C1 free cash flow for Q4 24 is -18.15 M CHF. For 2024, 6C1 free cash flow was -78.6 M CHF and operating cash flow was -78.31 M CHF.

Q1 '17

Q2 '17

Q3 '17

Q4 '17

Q1 '18

Q2 '18

Q3 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: CHF